Literature DB >> 27726949

Exceptional Duration of Radium-223 in Prostate Cancer With a BRCA2 Mutation.

Allie E Steinberger1, Patrick Cotogno1, Elisa M Ledet1, Brian Lewis1, Oliver Sartor2.   

Abstract

Entities:  

Keywords:  BRCA2; Mutation; Prostate cancer; Radium-223; mCRPC

Mesh：

Substances：

Year:  2016        PMID： 27726949     DOI： 10.1016/j.clgc.2016.09.001

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  8 in total

Review 1.  PARP inhibitors for homologous recombination-deficient prostate cancer.

Authors:  Eric S Christenson; Emmanuel S Antonarakis
Journal:  Expert Opin Emerg Drugs       Date:  2018-04-04       Impact factor: 4.191

Review 2.  Treatment strategies for DNA repair-deficient prostate cancer.

Authors:  Benjamin A Teply; Emmanuel S Antonarakis
Journal:  Expert Rev Clin Pharmacol       Date:  2017-06-12       Impact factor: 5.045

3.  Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.

Authors:  Pedro Isaacsson Velho; Fahad Qazi; Sayeedul Hassan; Michael A Carducci; Samuel R Denmeade; Mark C Markowski; Daniel L Thorek; Theodore L DeWeese; Daniel Y Song; Phuoc T Tran; Mario A Eisenberger; Emmanuel S Antonarakis
Journal:  Eur Urol       Date:  2018-10-04       Impact factor: 20.096

Review 4.  Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications.

Authors:  Naoki Terada; Shusuke Akamatsu; Takashi Kobayashi; Takahiro Inoue; Osamu Ogawa; Emmanuel S Antonarakis
Journal:  Ther Adv Med Oncol       Date:  2017-07-05       Impact factor: 8.168

Review 5.  Radium and other alpha emitters in prostate cancer.

Authors:  Oliver Sartor; Deepali Sharma
Journal:  Transl Androl Urol       Date:  2018-06

6.  Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.

Authors:  Oliver Sartor; Daniel Heinrich; Neil Mariados; Maria José Méndez Vidal; Daniel Keizman; Camilla Thellenberg Karlsson; Avivit Peer; Giuseppe Procopio; Stephen J Frank; Kalevi Pulkkanen; Eli Rosenbaum; Stefano Severi; José Trigo; Lucia Trandafir; Volker Wagner; Rui Li; Luke T Nordquist
Journal:  Prostate       Date:  2019-08-23       Impact factor: 4.104

7.  Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases.

Authors:  O Sartor; D Heinrich; N Mariados; M J Méndez Vidal; D Keizman; C Thellenberg Karlsson; A Peer; G Procopio; S J Frank; K Pulkkanen; E Rosenbaum; S Severi; J M Trigo Perez; V Wagner; R Li; L T Nordquist
Journal:  Ann Oncol       Date:  2017-10-01       Impact factor: 32.976

Review 8.  Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data.

Authors:  Dawid Sigorski; Ewa Iżycka-Świeszewska; Lubomir Bodnar
Journal:  Target Oncol       Date:  2020-12       Impact factor: 4.493
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.